Corvus Pharma Com (CRVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
| 06-2018 | 03-2018 | 12-2017 | 09-2017 | 06-2017 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -25,932 | -14,301 | -55,663 | -43,734 | -31,017 |
| Depreciation Amortization | 207 | 175 | 647 | 446 | 299 |
| Accounts payable and accrued liabilities | -1,199 | 45 | 1,554 | 1,712 | 2,322 |
| Other Working Capital | 484 | 1,395 | 2,575 | 3,565 | 3,270 |
| Other Operating Activity | 4,506 | 1,641 | 4,675 | 2,778 | 667 |
| Operating Cash Flow | $-21,934 | $-11,045 | $-46,212 | $-35,233 | $-24,459 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -59,976 | 3,626 | 85,092 | 74,427 | 53,728 |
| PPE Investments | -60 | -6 | -266 | -274 | -232 |
| Investing Cash Flow | $-60,036 | $3,620 | $84,826 | $74,153 | $53,496 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 64,932 | 64,884 | 1,442 | 134 | 8 |
| Financing Cash Flow | $64,932 | $64,884 | $1,442 | $134 | $8 |
| Beginning Cash Position | 45,106 | 45,106 | 5,050 | 5,050 | 5,050 |
| End Cash Position | 28,068 | 102,565 | 45,106 | 44,104 | 34,095 |
| Net Cash Flow | $-17,038 | $57,459 | $40,056 | $39,054 | $29,045 |
| Free Cash Flow | |||||
| Operating Cash Flow | -21,934 | -11,045 | -46,212 | -35,233 | -24,459 |
| Capital Expenditure | -60 | -6 | -266 | -274 | -232 |
| Free Cash Flow | -21,994 | -11,051 | -46,478 | -35,507 | -24,691 |